Clinical trials: Moderate Plaque Psoriasis
Plaque Psoriasis
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.
- Trial name
- ADMIRE (NCT06512337)
- Testing
- Deucravacitinib
- Where
- 5 sites in China
- Volunteers
- 153 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis
This clinical trial will evaluate the efficacy and safety of Clobex® (clobetasol propionate) Spray 0.05% and Vectical™ (calcitriol) Ointment 3 µg/g over a four week period of use in one of two different regimens: 1.
- Trial name
- NCT00988637
- Testing
- Vectical™ Ointment weekdays and Clobex® Spray weekends regimen, Clobex® Spray morning and Vectical™ Ointment evening regimen
- Where
- 6 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult…
- Trial name
- NCT03298581
- Testing
- Halobetasol Propionate
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis, Skin Diseases
Study to Assess the Efficacy and Safety of Orismilast in Psoriasis
This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe plaque-type psoriasis.
- Trial name
- IASOS (NCT05190419)
- Testing
- Orismilast modified release tablets
- Where
- 34 sites in United States, Germany and 2 more
- Volunteers
- 202 people
- Sponsor
- UNION therapeutics
Plaque Psoriasis
TSO for Plaque Psoriasis
This is a randomized, blinded, multicenter study to assess the safety and treatment effect of 12 weeks of Trichuris suis ova in subjects diagnosed with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02011269
- Testing
- Trichuris Suis Ova
- Sponsor
- Coronado Biosciences, Inc.
Psoriasis
A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to compare the safety and efficacy of risankizumab to methotrexate in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT03219437
- Testing
- risankizumab, methotrexate
- Where
- 11 sites in Brazil
- Volunteers
- 104 people
- Sponsor
- AbbVie
Moderate to Severe Plaque Psoriasis
A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis
The primary objective of this study is to evaluate the efficacy of HS-20118 compared with placebo in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT07765628
- Testing
- HS-20118
- Volunteers
- 120 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Plaque Psoriasis, Crohn's Disease
Adalimumab-psoriasis and Small Bowel Lesions
This study will determine the prevalence of small bowel lesions suggestive of Crohn's disease (CD) in patients with moderate to severe plaque psoriasis using capsule endoscopy.
- Trial name
- NCT01556672
- Testing
- Adalimumab, Capsule endoscopy
- Where
- 3 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Innovaderm Research Inc.
Psoriasis
A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis
A double-blind, placebo-controlled, randomized, parallel-group study to evaluate the activity of oral AB1010 in adults patients with moderate to severe chronic plaque psoriasis
- Trial name
- NCT01045577
- Testing
- Masitinib
- Volunteers
- 25 people
- Sponsor
- AB Science
Moderate to Severe Plaque Psoriasis
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses
- Trial name
- AMAGINE-2 (NCT01708603)
- Testing
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab
- Where
- 153 sites in United States, Australia and 9 more
- Volunteers
- 1,831 people
- Sponsor
- Bausch Health Americas, Inc.
Plaque Psoriasis
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT02899988
- Testing
- Mirikizumab
- Where
- 40 sites in United States, Canada and 4 more
- Volunteers
- 205 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in participants with moderate-to-severe plaque psoriasis .
- Trial name
- NCT06278350
- Testing
- D-2570
- Where
- China
- Volunteers
- 161 people
- Sponsor
- InventisBio Co., Ltd
Plaque Psoriasis
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis
This Phase 2 study has been designed to determine and compare the safety, tolerability, and efficacy of DUR-928 topical solution with that of the vehicle topical solution when applied once daily for approximately four weeks in…
- Trial name
- NCT03837743
- Testing
- DUR-928 Topical Solution, Vehicle Topical Solution
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Durect
Plaque Psoriasis
A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis
This is a two-arm, parallel group, double-blind, placebo-controlled proof-of-concept study comparing 3 mg/kg of AIN457 to placebo.
- Trial name
- NCT00669916
- Testing
- AIN457
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis
The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with moderate to severe plaque psoriasis.
- Trial name
- NCT07008547
- Testing
- Netakimab
- Where
- China
- Volunteers
- 202 people
- Sponsor
- SPH-BIOCAD (HK) Limited
Chronic Plaque Psoriasis
To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly…
- Trial name
- NCT07337434
- Testing
- Methotrexate, Apremilast
- Where
- Pakistan
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Syeda Sana Zaman
Psoriasis
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
- Trial name
- N/Z (NCT07489885)
- Testing
- D-2570 Tablet
- Where
- 20 sites in United States
- Volunteers
- 75 people
- Sponsor
- InventisBio Co., Ltd
Plaque Psoriasis
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to <18 years with moderate to severe plaque psoriasis.
- Trial name
- NCT04772079
- Testing
- Deucravacitinib
- Where
- 65 sites in Argentina, Australia and 11 more
- Volunteers
- 153 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for…
- Trial name
- NCT03875508
- Testing
- Risankizumab, Autoinjector
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- AbbVie
Plaque Psoriasis Vulgaris
Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis
The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.
- Trial name
- DERMIS (NCT03310320)
- Testing
- AZD0284 oral solution 2.5 mg/mL
- Where
- 4 sites in Denmark
- Volunteers
- 9 people
- Sponsor
- AstraZeneca